Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Financings
Financings
| Raise | Date |
|---|---|
| Public offering of shares of common stock Closed: US$80.5M raised · US$5 a share · Piper Sandler +3 Dealers: Piper Sandler (co-lead), TD Cowen (co-lead), BTIG, H.C. Wainwright & Co. Use of proceeds: Fund AVIM Therapy program and BACKBEAT Trial, Virtue SAB program and Virtue Trial, other R&D, working capital and general corporate purposes | Nov 10, 2026 |
| Public offering of shares of common stock Announced: Piper Sandler +2 Dealers: Piper Sandler (co-lead), TD Cowen (co-lead), BTIG Use of proceeds: Fund AVIM Therapy program and BACKBEAT trial, Virtue SAB program and Virtue Trial, other R&D, working capital and general corporate purposes | Nov 5, 2026 |
| Strategic investment of strategic capital Closed: US$35M raised Buyers: Medtronic (Medtronic's total capital contribution to Orchestra BioMed is nearly $82 million, including this investment); Ligand (Ligand has now provided $40 million in total capital to the Company) | Aug 10, 2026 |
| Strategic investment of non-voting convertible preferred stock Announced: US$20M Buyers: Terumo ($20 million in a new series of non-voting preferred stock) Use of proceeds: Advance both pivotal stage programs to key clinical and regulatory milestones | Oct 28, 2025 |
| Public offering of common stock and pre-funded warrants Announced: about US$40M · US$2.75 a share · Piper Sandler +1 Dealers: Piper Sandler (co-lead), TD Cowen (co-lead) Use of proceeds: Fund AVIM therapy program and BACKBEAT study, Virtue SAB program and trial, other product candidates, working capital and general corporate purposes | Aug 1, 2025 |
| Tiered royalty on future sales of AVIM therapy and Virtue SAB Announced: US$35M Buyers: Ligand ($20 million at closing and an additional $15 million at the nine-month anniversary, subject to conditions) Use of proceeds: To advance its late-stage partnered cardiology programs (AVIM therapy and Virtue SAB) | Jul 31, 2025 |
| Private placement of common stock Announced: US$5M Buyers: Ligand ($5 million of common stock) | Jul 31, 2025 |
| Private placement of common stock Announced: US$10M Buyers: Medtronic ($10 million of common stock) | Jul 31, 2025 |
| Secured subordinated promissory note convertible to prepaid revenue share Announced: US$20M Buyers: Medtronic ($20 million secured subordinated promissory note) | Jul 31, 2025 |